Adequacy of samples obtained via percutaneous core-needle rebiopsy for EGFR T790M molecular analysis in patients with non-small cell lung cancer following acquired resistance to first-line therapy: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Adequacy of samples obtained via percutaneous core-needle rebiopsy for EGFR T790M molecular analysis in patients with non-small cell lung cancer following acquired resistance to first-line therapy: A systematic review and meta-analysis

Published:2021 Issue: Volume:29 Page:100470
ISSN:2468-2942
Container-title:Cancer Treatment and Research Communications
language:en
Short-container-title:Cancer Treatment and Research Communications

Author:

Poudel Bibhav,Desman Jacob,Aihara Gohta,Weidman Deborah I.,Tsang Ashley,Kovrizhkin Katherine,Pereira Tatiana,Arun Siddharth,Pradeep Tejus,Matin Shababa,Liddell Robert P.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference55 articles.

1. Centers for disease control and prevention;Lung Cancer Stat,2020

2. Cancer statistics;Siegel;CA Cancer J. Clin,2019

3. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades;Lu;Cancer Manag. Res,2019

4. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC);Gelatti;Lung Cancer,2019

5. Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma;Rangachari;J. Thorac. Oncol,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer;Diagnostics;2022-12-30

2. Endobronchial ultrasound‐guided re‐biopsy of non–small cell lung cancer with acquired resistance after EGFR tyrosine kinase inhibitor treatment;Thoracic Cancer;2022-12-16

3. Role of Image-Guided Percutaneous Needle Biopsy in the Age of Precision Medicine;Current Oncology Reports;2022-04-01